The same series of competitive experiments were carried out to study the inhibition of the trans-infection phenomenon with SARS-CoV-2 (Fig. ). The inhibition of DC-SIGN mediated trans-infection is even lower than in the EBOV experiments for all ligands at both the tested concentrations (here between 1% and 19% inhibition vs. 7% to 33% for EBOV), which is not the case for L-SIGN, further emphasizing the selectivity of Man084-derived PMs (PM69 and PM74). The dose-dependent effect is less pronounced for this panel of experiments: while PM69 and PM74 respectively inhibit infection by 98.5 and 94.6% at 5 µM, they still achieve an inhibition of 97 and 92% for a 10-fold lower dose, showing the tool's efficacy. In addition, for the SARS-CoV-2 experiments, we did not observe any differences in selectivity, whether the linker is short or long. However, given the topology of the active sites (Fig. ), this factor should not be ruled out for future uses of these compounds.